Sandra and Edward Meyer Cancer Center

Postmenopausal women with higher levels of body fat have a significantly increased risk of developing breast cancer even if they have a normal body mass index (BMI), according to a new study.

A study of the dual pathways that process the essential vitamin folate by Weill Cornell Medicine investigators unexpectedly revealed a new way the cancer drug methotrexate works and may suggest strategies to boost its cancer-killing effects.

Dr. Massimo Loda Appointed Chair of the Department of Pathology and Laboratory Medicine at Weill Cornell Medicine and Pathologist-in-Chief at NewYork-Presbyterian/Weill Cornell Medical Center

Weill Cornell Medicine investigators Dr. David Lyden and Dr. Ari Melnick have been awarded Outstanding Investigator Awards from the National Cancer Institute.

Ovarian tumors disable the immune system’s killer T cells—which protect the body by destroying infected or malignant cells—enabling the disease to flourish unchecked, according to a new study by Weill Cornell Medicine scientists.

Dr. Dan Landau has received a New Innovator Award from the National Institutes of Health for his research on how tumor cells evolve and acquire new mutations to evade cancer therapies.

A very low carbohydrate, high-fat diet called the ketogenic diet may improve the effectiveness of an emerging class of cancer drugs, according to a study in mice by investigators at Weill Cornell Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian.

A new cellular messenger discovered by Weill Cornell Medicine scientists may help reveal how cancer cells co-opt the body’s intercellular delivery service to spread to new locations in the body.

Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center researchers.

Many successful researchers cite the influence of a mentor who inspired and advised them—and that’s especially true for Dr. Kevin O’Rourke, PhD ’17.

Ongoing monitoring for genetic changes in chronic lymphocytic leukemia (CLL) during targeted treatment may allow clinicians to adjust patients’ treatments as the cancer evolves, according to a study in Nature Communications led by Weill Cornell Medicine and New York Genome Center scientists.

When Dr. Onyinye Balogun was a young girl, her father’s only sister was diagnosed with breast cancer back home in their native Nigeria. Dr. Balogun had recently immigrated to the United States with her parents, but on a return visit the severity of her aunt’s disease became clear.

Internationally renowned neuro-oncologist Dr. Howard A. Fine of Weill Cornell Medicine and NewYork-Presbyterian will receive a five-year, $6 million National Institutes of Health Director’s Pioneer Award for brain cancer research.

Weill Cornell Medicine has been awarded a five-year, $11.3 million Specialized Programs of Research Excellence grant from the National Cancer Institute to improve the detection, diagnosis and treatment of prostate cancer. 

Genetic mutations caused by rearranged chromosomes drive the development and growth of certain colorectal cancers, according to new research conducted by Weill Cornell Medicine investigators.

Growing up in Knoxville, Tennessee, Neel Madhukar always assumed he would become a physician.

Stem cells preserve their identities after cell division by using a series of protein “bookmarks” on their genes,...

Researchers have long struggled to develop preclinical models of colorectal cancer in which the disease forms in the correct anatomical location.

Weill Cornell Medicine and NewYork-Presbyterian have been named to the nonprofit Stand Up 2 Cancer’s Colorectal Dream Team to drive new advances in colorectal cancer research and treatment.

A newly discovered genetic mutation that is found in a subtype of prostate cancer is integral to the disease’s development and growth.